STOCKHOLM, Sweden, Nov. 2, 2005 (PRIMEZONE) -- Active Biotech:
-- Laquinimod safe at higher dose for MS patients -- Longer survival rate for renal cancer patients treated with first-generation ANYARA -- Confirmed ANYARA tumor localization in cancer patients -- Expanded TASQ clinical studies for prostate cancer patients -- SLE 57-57 project; ready to initiate patient studies -- Acquisition of research facility in Lund -- Net sales: SEK 6.5 M (68.2) -- Operating loss: SEK 92.2 M (loss: 126.6) -- Loss after tax: SEK 91.9 M (loss: 109.5) -- Loss per share for the period: SEK 2.58 (loss: 3.16)
To view the full press release: http://hugin.info/1002/R/1019179/160218.pdf